Paclitaxel Has a Reduced Toxicity Profile in Healthy Rats After Polymeric Micellar Nanoparticle Delivery

BACKGROUND: Nanocarrier platforms have been indicated to have great potential in clinical practice to treat non-small cell lung cancer (NSCLC). Our previous Phase III clinical study revealed that polymeric micellar paclitaxel (Pm-Pac) is safe and efficacious in advanced NSCLC patients. However, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Jun, Lou, Yuqing, Zhang, Yanwei, Zhong, Runbo, Zhang, Wei, Zhang, Xueyan, Wang, Huimin, Chu, Tianqing, Han, Baohui, Zhong, Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844231/
https://www.ncbi.nlm.nih.gov/pubmed/36660338
http://dx.doi.org/10.2147/IJN.S372961

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844231/
https://www.ncbi.nlm.nih.gov/pubmed/36660338
http://dx.doi.org/10.2147/IJN.S372961

Ejemplares similares